TLP
AERI

Tri Locum Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Tri Locum Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-68,472
Closed -$1.22M – 45
2021
Q1 		$1.22M Buy
+68,472
New +$1.18M 0.3% 32

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Tri Locum Partners's AERI Position: Q2 2021 in Review

Tri Locum Partners sold out of Aerie Pharmaceuticals (AERI) in Q2 2021, closing a stake of 68,472 shares — an estimated $1.22M sold.

Tri Locum Partners first reported a position in AERI in Q1 2021 and held it in 1 quarter. The position peaked at $1.22M in Q1 2021. 142 funds tracked by Wall St. Rank hold AERI as of Q2 2021.

  • Tri Locum Partners reported no remaining Aerie Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Tri Locum Partners sold 68,472 Aerie Pharmaceuticals shares in Q2 2021, an estimated $1.22M.
  • Tri Locum Partners first reported a position in Aerie Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Tri Locum Partners's Aerie Pharmaceuticals position peaked at $1.22M in Q1 2021.
  • 142 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2021.

Based on Tri Locum Partners's 13F filing for Q2 2021, filed 16 Aug 2021.